FR2761688A1 - New adenovirus with mutations in the fibre protein to alter binding selectivity - Google Patents

Abstract

New adenovirus (Ad) fibre (A) has at least one mutation in residues that are involved in binding to the natural cellular receptor of AD, present between the CD loop and beta -sheet I of the fibre, particularly between the CD and DG loops. Also new are: (1) Ad fibre (A') having significantly reduced ability to bind the natural cellular receptor and able to trimerise; (2) DNA fragments (II) or expression vectors encoding (A) or (A'); (3) cell lines having (II) integrated into the genome, or in episomal form, under control of expression elements; (4) Ad lacking a functional native fibre but including (A) or (A'), encoded by the viral genome or provided in trans by the cells of (3), and optionally also a ligand (III) that recognises a cell surface molecule other than the natural receptor; and (5) host cells infected with Ad of (4).

Description

 The subject of the present invention is an adenoviral fiber mutated in the regions involved in the recognition and binding of the natural cellular receptor of adenoviruses. It also relates to recombinant adenoviruses carrying on their surface such a fiber and a ligand which confers on them a host specificity modified or targeted towards a particular cell type, the cells containing these adenoviruses as well as a method for preparing infectious viral particles of these are intended for therapeutic use. The invention is of particular interest for gene therapy perspectives, particularly in humans.

 Due to their particular properties, adenoviruses are used in a growing number of applications in gene therapy. In many animal species, they are not very pathogenic, non-integrative and replicate in both dividing and quiescent cells. In addition, they have a broad host spectrum and are capable of infecting a very large number of cell types such as epithelial, endothelial, myocyte, hepatocyte, nerve cell and synoviocyte cells (Bramson et al., 1995, Curr.

Op. Biotech. 6, 590-595). However, this lack of specificity of infection could constitute a limit to the use of recombinant adenoviruses, on the one hand, in terms of safety since there can be dissemination of the recombinant gene in the host organism and, on the other hand, in terms of efficacy since the virus does not specifically infect the cell type that one wishes to treat.

In general, the adenoviral genome consists of a linear, double-stranded DNA molecule of about 36 kb containing the genes encoding the viral proteins and at its ends two inverted repeats (designated RTIs for
Inverted Terminal Repeat) involved in the replication and encapsidation region.

The early genes are divided into 4 regions dispersed in the adenoviral genome (E1 to E4, E for early in English), comprising 6 transcriptional units with their own promoters. The late genes (L1 to L5; L for late in English) partially cover the early transcription units and are, for the most part, transcribed from the late major promoter MLP (for Major Late Promoter in English).

 As a vindictive, all the adenoviruses used in the gene therapy protocols are deficient for deletion replication of at least the E1 region and are propagated in a complementation cell line, which provides in trans the deleted viral functions. The 293 line, made from human embryonic kidney cells, is commonly used which effectively complements the E1 function (Graham et al., 1977, J. Gen. Virol 36, 59-72). Second generation vectors have recently been proposed in the literature. They preserve the cis regions necessary for the replication of the virus in the infected cell (ITRs and encapsidation sequences) and include important internal deletions aimed at removing the essential viral genes whose expression in vivo can lead to establishment of inflammatory or immune responses in the host. The adenoviral vectors and their preparation technique have been the subject of numerous publications accessible to those skilled in the art.

 The infectious cycle of adenoviruses occurs in 2 stages. The early phase precedes the initiation of replication and allows the production of early proteins that regulate the replication and transcription of viral DNA. The replication of the genome is followed by the late phase during which the structural proteins that constitute the viral particles are synthesized. The assembly of the new virions takes place in the nucleus. In a first step, the viral proteins assemble to form empty capsids of icosahedral structure in which the genome is encapsidated. The adenoviruses released are likely to infect other permissive cells. In this respect, the fiber and the penton base present on the surface of capsids play a critical role in the cellular attachment of virions and their internalization.

 Adenovirus binds to a cell receptor present on the surface of permissive cells via the trimeric fiber (Philipson et al., 1968, J. Virol.

2, 1064-1075; Defer et al., 1990, J. Virol. 64, 3661-3673). The particle is then internalized by endocytosis by the binding of the penton base to the avss3 and avsss cellular integrins (Mathias et al., 1994, J. Virol 68, 6811-6814). The ability of soluble fiber or anti-fiber antibodies to inhibit infection demonstrates its role in cellular attachment of the virus.

 The fiber is composed of 3 domains (Chroboczek et al., 1995, Current Top.

Microbiol. Immunol. 199, 165-200): (1) In N-terminal, the highly conserved tail from one serotype to another, interacts with the
penton base and ensures the anchoring of the molecule in the capsid.

(2) The stem is a rod structure composed of a number of
ss leaflet repetitions, this number varying according to the serotypes.

(3) Finally, at the distal end of the stem, the head is a globular structure
spherical which contains the trimerization signals (Hong and Engler, 1996, J.

Virol. 70, 7071-7078; Novelli and Boulanger, 1991, J. Biol. Chem. 266, 9299
9303; Novelli and Boulanger, 1991, Virology 185, 365-376). In addition, most
experimental data show that the domain of the head is
responsible for permissive cell binding (Henry et al., 1994, J. Virol
68, 5239-5246; Louis et al., 1994, J. Virol. 68, 4104-4106).

 "Targeted" adenoviruses whose native fiber is modified to recognize a different cell receptor have already been proposed in the literature.

Thus, WO94 / 10323 discloses mutants of the AdS fiber in which a sequence encoding an antibody fragment (scFv type) is inserted at the end of one of the 22 repetitive units of the stem for the purpose of modify the specificity of infection with respect to the cells presenting the target antigen. No. 5,543,328 describes an Ad5 chimeric fiber in which the head domain is replaced by tumor necrosis factor (TNF) so as to interact with the TNF cellular receptor. In another construction, the native Ad5 fiber is fused at its C-terminus to the ApoE peptide allowing binding to the LDL (low density lipoprotein) receptor present on the surface of the liver cells. WO95 / 26412 discloses a ligand-modified fiber at the C-terminus which retains its trimerization capabilities. WO96 / 26281 describes a chimeric fiber obtained by replacing part of the native fiber and, in particular the head, with the equivalent part of an adenoviral fiber of another serotype and, optionally, by insertion at the end C-terminal of a RGD peptide specific for vitronectin.

 As previously indicated, the specificity of infection of an adenovirus is determined by the attachment of the adenoviral fiber to a cell receptor located on the surface of the permissive cells. The French patent application 97 01005 has highlighted the role of major histocompatibility complex antigens class I and III fibronectin modules as a primary receptor and adenovirus cofactor respectively. But other proteins can intervene. The problem that the present invention proposes to solve is to modify the interaction region of the adenoviral fiber with the cellular receptor in order to alter the natural host specificity of the adenoviruses carrying the mutated fiber. The addition of a ligand makes it possible to confer a new tropism towards one or more specific cell types bearing on their surface a target molecule recognized by the ligand in question.

 The present invention is an improvement of the prior art since it discloses the region of the fiber to be mutated to inhibit or prevent binding to the natural cellular receptor of adenoviruses. One or more residues from region 443 to 462 of the AdS fiber head have now been substituted or deleted, and an inhibition of the infectivity of corresponding adenoviruses with respect to normally permissive cells has been demonstrated. The introduction of the ligand GRP (for gastrin releasing peptide in English) within this fiber allows the infection of cells expressing the receptor GRP. The aim of the present invention is to reduce the therapeutic quantities of adenovirus to be used and to target the infection at the level of the cells to be treated. This specificity is indispensable when an adenovirus expressing a cytotoxic gene is used to prevent the spread of the cytotoxic effect to healthy cells. The advantages provided by the present invention are to reduce the risks of dissemination and the side effects related to adenoviral technology.

 This is why the present invention relates to a fiber of an adenovirus modified by mutation of one or more residues of said fiber, characterized in that said mutated residues are directed towards the natural cellular receptor of said adenovirus.

The term "fiber" is broadly defined in the introductory part. The fiber of the present invention may be derived from an adenovirus of human, canine, avian, bovine, murine, ovine, porcine or simian origin or may be hybridized and include fragments of various origins. As regards human adenoviruses, it is preferred to use those of serotype C and, in particular, adenoviruses of type 2 or 5 (Ad2 or Ad5). Ad2 fiber is indicated to have 580 amino acids (aa) whose sequence is disclosed in Herissé et al. (1981, Nucleic Acid Res 9, 40234042). That of AdS has 582 aa and its sequence presented at sequence identifier 1 (SEQ ID NO: 1) was determined by Chroboczek and Jacrot (1987,
Virology 161, 549-554). When the fiber of the present invention originates from an animal adenovirus, bovine adenoviruses and, in particular, those of strain BAV-3 are preferably used. These have been the subject of numerous studies and the sequence of the fiber is disclosed in international application WO95 / 16048. Of course, the fiber of the present invention may have other modifications relative to the native sequence, in addition to those which are the subject of the present invention.

 In accordance with the objects pursued by the present invention, the fiber according to the invention is modified so as to reduce or abolish its binding capacity to the natural cellular receptor. Such a property can be verified by studying the infectivity or cellular binding of the corresponding viruses by applying the techniques of the art such as those detailed below. According to an advantageous embodiment, the trimerization and penton-base binding properties are not affected.

 For the purposes of the present invention, the term "mutation" denotes a deletion, a substitution or an addition of one or more residues or a combination of these possibilities. Particularly preferred is the case where the regions of interaction with the natural cellular receptor are deleted in whole or in part and replaced in particular by a ligand specific for a cell surface protein other than the natural adenovirus receptor.

 The three-dimensional crystallographic structure of the adenoviral head was determined by Xia et al. (1994, Structure 2, 1259-1270). Each monomer has 8 antiparallel antiparallel sheets designated A to D and G to J and 6 major loops of 8 to 55 residues. For example, the CD loop connects the slip ss C to the slip ss D.

It is indicated that the minor leaflets E and F are considered to be part of the DG loop between the D and G sheets. As an indication, Table 1 indicates the location of these structures in the amino acid sequence of the fiber. AdS as shown at the sequence identifier n0 i (SEQ ID NO: 1), the +1 representing the initiator Met residue. In general, the sheets form an orderly and compact structure while the loops are more flexible. These terms are conventional in the field of protein biochemistry and are defined in basic literature (see, for example, Stryer, Biochemistry, 2nd edition,
Chap 2, p 11 to 39, Ed Freeman and Compagny, San Francisco).

Table 1

<tb><SEP> slip <SEP> ss <SEP> loop
<tb> nomenclature <SEP> residues <SEP> nomenclature <SEP> residues
<tb><SEP> A <SEP> 400 <SEP> to <SEP> 403 <SEP> AB <SEP> 404 <SEP> to <SEP> 418
<tb><SEP> B <SEP> 419-428 <SEP>
<tb><SEP> C <SEP> 431-440 <SEP> CD <SEP> 441-453 <SEP>
<tb><SEP> D <SEP> 454 to 461 <SEP> DG <SEP> 462 <SEP> to <SEP> 514
<tb><SEP> G <SEP> 515to521 <SEP> GH <SEP> 522to528 <SEP>
<tb><SEP> H <SEP> 529to536 <SEP> HI <SEP> 537to549 <SEP>
<tb><SEP> I <SEP> 550 <SEP> to <SEP> 557 <SEP> IJ <SEP> 558to572 <SEP>
<tb><SEP> J <SEP> 573to578 <SEP>
<Tb>
The four sheets ss A, B, C and J constitute the sheets V directed towards the viral particle. The other four (D, G, H and I) form the R sheets, supposed to face the cellular receptor. V-sheets appear to play an important role in the trimerization of the structure whereas the R-sheets would be involved in the interaction with the receptor. Residues of the Ad2 fiber, Ad3, Ad5, Ad7, Ad40,
Ad41 and CAV canine adenovirus forming these different structures are clearly indicated in the previous reference.

 The modifications of the adenoviral fiber according to the invention more particularly affect the field extending from the CD loop to the sheet I and concern in particular the residues 441 to 557 of the Ad5 fiber and 441 to 558 of the Ad2 fiber. Because of their spatial location in the native fiber, these residues are capable of recognizing and / or interacting directly with the indirect cellular receptor of the adenovirus concerned. Within this region, it is preferred to modify the part that comprises the CD loop, the sheet D and the proximal portion of the DG loop (positions 441 to 478 of the Ad2 and AdS fiber) and, more particularly, the region ranging from residues 443 to 462 for Ad5 or 451 to 466 in the case of Ad2.

 As indicated above, one can operate by substitution of one or more amino acids in the exposed regions. The following examples which derive from the Ad5 fiber in which: the glycine residue at position 443 is substituted by an aspartic acid, the leucine residue at position 445 is substituted by a phenylalanine, the residue is substituted. glycine at position 450 is substituted by an asparagine, - the threonine residue at position 451 is substituted by a lysine, - the valine residue at position 452 is substituted by an asparagine, - the alanine residue at position 455 is substituted by a phenylalanine, - the leucine residue at position 457 is substituted with alanine, and / or - the isoleucine residue at position 459 is substituted with alanine.

 It is also possible to introduce several substitutions within the targeted region of the fiber, especially at the level of the elbow-forming amino acids, preferably of the aa type (see Table 2 of Xia et al., 1994, supra). To illustrate, there are two examples in which the Ad5 fiber is modified by substitution - of the glycine residue at position 443 by an aspartic acid, - of the serine residue at position 444 with a lysine, and - of the alanine residue in position 446 with threonine.

or
the serine residue at position 449 with an aspartic acid, the glycine residue at position 450 with a lysine, the threonine residue at position 451 with a leucine, and the valine residue at position 452 with a threonine.

 Of course, the replacement amino acids are merely indicative and any amino acid may be suitable for the purpose of this invention. However, it is preferred not to modify drastically the three-dimensional structure.

Preferably, the amino acids forming a bend will be replaced by residues forming a similar structure such as those mentioned in the reference Xia et al. already mentioned.

The fiber of the present invention may also be modified by deletion. The eliminated region may concern all or part of the exposed area and, in particular, the CD loop, the D-sheet and / or the DG loop. As regards an Ad5 fiber according to the invention, mention may be made more particularly of the deletion of: the region extending from the serine at position 454 to the phenylalanine in
position 461, - from the region extending from valine at position 441 to glutamine in position
453, or the region extending from valine at position 441 to phenylalanine in
heading 461.

 According to an advantageous embodiment, when at least one of the modifications is a deletion of at least 3 consecutive residues of a loop and / or a leaflet, the deleted residues can be replaced by residues of a loop. and / or an equivalent leaflet derived from a fiber of a second adenovirus capable of interacting with a cellular receptor different from that recognized by the first adenovirus. This makes it possible to maintain the structure of the fiber according to the invention while conferring on it a host specificity corresponding to that of the second adenovirus.

As reported in Xia et al. (1994, supra), the cell receptor mediating the infection of adenovirus types 2 and 5 is different from that interacting with type 3 and 7 adenoviruses. Thus, an Ad5 or Ad2 fiber deleted from at least 3 consecutive residues among those specified above may be substituted by residues from an equivalent region of the Ad3 or Ad7 fiber to reduce its ability to bind the Ad5 receptor and confer new specificity on it. the Ad3 or Ad7 cell receptor. By way of non-limiting example, there may be mentioned the replacement of LAPISGTVQSAHLIIRFD residues (positions 445 to 462) of the Ad5 fiber by the residues VNTLFKNKNVSINVELYFD of the Ad3 fiber.

 The present invention also relates to an adenovirus fiber having a substantially reduced natural cell receptor binding capacity and yet capable of trimerizing.

 According to an equally advantageous embodiment, the fiber according to the invention further comprises a ligand. For the purposes of the present invention, the term ligand defines any entity capable of recognizing and binding, preferably with high affinity, a cell surface molecule different from the natural cellular receptor. This molecule can be expressed or exposed on the surface of the cell that it is desired to target (cell surface marker, receptor, antigenic peptide presented by the histocompatibility antigens, etc.). In accordance with the aims pursued by the present invention, a ligand may be an antibody, a peptide, a hormone, a polypeptide or a sugar. The term antibody includes, in particular, monoclonal antibodies, antibody fragments (Fab) and single chain antibodies (scFv).

These denominations and abbreviations are conventional in the field of immunology.

 In the context of the present invention, it may be advantageous to target more particularly a tumor cell, an infected cell, a particular cell type or a class of cells carrying a specific surface marker.

For example, if the host cell to be targeted is a cell infected with the HIV (Human Immunodeficiency Virus), the ligand can be an antibody fragment against the fusine, the CD4 receptor or against an exposed viral protein (envelope glycoprotein). ) or the portion of the TAT protein of the HIV virus extending residues 37 to 72; (Fawell et al., 1994, Proc Natl Acad Sci USA 91, 664-668).

As regards a tumor cell, the choice will be made on a ligand recognizing a tumor-specific antigen (for example the MUC-1 protein in the case of breast cancer, certain epitopes of the HPV papilloma virus E6 or E7 proteins). or overexpressed (IL-2 receptor overexpressed in certain lymphoid tumors).

If it is desired to target T cells, a T-cell receptor ligand can be employed. Transferrin is also a good candidate for hepatic targeting.

In general, ligands that can be used in the context of the invention are widely described in the literature and can be cloned by standard techniques. It is also possible to synthesize them chemically and couple them to the fiber according to the invention. In this respect, galactosyl residues coupling should confer liver specificity due to interaction with asialoglycoprotein receptors. But the preferred embodiment consists in inserting the ligand at the C-terminal end of the fiber according to the invention or replacing the deleted residues when at least one of the modifications is a deletion of at least 3 consecutive residues.

 The present invention also relates to a DNA fragment coding for a fiber according to the invention as well as to an expression vector of such a fragment. Any type of vector can be used for this purpose, whether of plasmid or viral origin, integrative or not. Such vectors are commercially available or described in the literature. Similarly, those skilled in the art are able to adapt the regulatory elements necessary for the expression of the DNA fragment according to the invention.

 The present invention also relates to an adenovirus devoid of a functional native fiber and which comprises on its surface a fiber according to the invention and a ligand as defined above. This may be expressed by the adenoviral genome or provided in trans by a complementation cell line, such as those defined below. Preferably, the binding specificity of such an adenovirus to its natural cellular receptor is reduced significantly or better abolished, because of the modified fiber it carries. The loss of the natural specificity can be evaluated by cell attachment studies carried out in the presence of labeled viruses (for example with 3H thymidine according to the technique of Roelvink et al., 1996, J. Virol.

70, 7614-7621) or by permissive cell infectivity studies or expressing the ligand-targeted surface molecule (see the following examples).

 The ligand can be chemically coupled to the adenovirus according to the invention. However, the variant according to which the sequences coding for the ligand are inserted into the adenoviral genome, in particular, within the sequences coding for the modified fiber according to the invention, preferably in phase in order to preserve the framework of reading. Insertion can take place anywhere.

Nevertheless, the preferred insertion site is upstream of the stop codon at the Cterminal end or in place of the deleted residues. It is also conceivable to introduce the ligand sequences into other adenoviral sequences, in particular those coding for another capsid protein, such as hexon or penton.

 Advantageously, an adenovirus according to the invention is recombinant and defective for replication, ie incapable of autonomous replication in a host cell. The deficiency is obtained by mutation or deletion of one or more essential viral genes and, in particular, all or part of the El region. Deletions within the E3 region can be envisaged to increase the cloning capacities.

However, it may be advantageous to retain the sequences encoding the 9k gene protein (Gooding and Wood, 1990, Critical Reviews of Immunology 10, 53-71) in order to modulate the immune responses of the host. Of course, the genome of an adenovirus according to the invention may also comprise additional deletions or mutations affecting other regions, in particular the E2, E4 and / or L1-L5 regions (see, for example, the international application WO94 / 28152). and Ensinger et al., 1972, J.

Virol. 10, 328-339 describing the thermosensitive mutation of the DBP gene of E2).

 According to a preferred embodiment, an adenovirus according to the invention is recombinant and comprises one or more gene (s) of interest placed (s) under the control of the elements necessary for its (their) expression in a host cell. The gene in question may be of any origin, genomic, cDNA (complementary DNA) or hybrid (minigene devoid of one or more introns). It can be obtained by conventional techniques of molecular biology or by chemical synthesis. It can encode an antisense RNA, ribozyme or mRNA which will then be translated into the polypeptide of interest. This may be cytoplasmic, membraneous or secreted from the host cell. Furthermore, it may be all or part of a polypeptide as found in nature, a chimeric polypeptide originating from the fusion of sequences of various origins, or a polypeptide mutated with respect to the sequence native having improved and / or modified biological properties.

In the context of the present invention, it may be advantageous to use the genes coding for the following polypeptides: cytokines or lymphokines (interferons a, ss and 7, interleukins and especially
IL-2, IL-6, IL-10 or IL-12, tumor necrosis factors (TNF), factors
colony stimulators (GM-CSF, C-CSF, M-CSF ...); - cellular or nuclear receptors, in particular those recognized by
pathogenic organisms (viruses, bacteria, or parasites) and, preferably, by the
HIV virus or their ligands; - proteins involved in a genetic disease (factor VII, factor VIII,
factor IX, dystrophin or minidystrophin, insulin, CFTR protein (Cystic
Fibrosis Transmembrane Conductance Regulator), growth hormones (hGH); - enzymes (urease, renin, thrombin ...); - enzyme inhibitors (al-antitrypsin, antithrombin III, inhibitors of
viral proteases ...); - anti-tumor effect polypeptides capable of inhibiting at least partially
initiation or progression of tumors or cancers (antibodies, inhibitors
acting at the level of cell division or transduction signals,
tumor suppressor gene expression products, for example p53 or
Rb, proteins stimulating the immune system ....); - major histocompatibility complex proteins class I or II or
regulatory proteins acting on the expression of the corresponding genes; - polypeptides capable of inhibiting a viral, bacterial or parasitic infection
or its development (antigenic polypeptides with
immunogens, antigenic epitopes, antibodies, trans-dominant variants
capable of inhibiting the action of a native protein by competition ...) - toxins (thymidine kinase of herpes simplex virus 1 (TK-HSV-1), ricin, cholera toxin, diphtheria) or immunotoxins; and - markers (β-galactosidase, luciferase, etc.).

 It should be noted that this list is not limiting and that other genes can also be used.

 Moreover, an adenovirus according to the invention may, in addition, comprise a selection gene for selecting or identifying the infected cells. Neo-genes (encoding neomycin phosphotransferase) conferring resistance to the antibiotic G418, dhfr (Dihydrofolate Reductase), CAT (Chloramphenicol Acetyl transferase), pac (Puromycin Acetyl-Transferase) or gpt (Xanthine Guanine Phosphoribosyl Transferase) may be mentioned. ). In general, the selection genes are known to those skilled in the art.

 By elements necessary for the expression of another ....) or its maintenance in the host cell. Such elements are known to those skilled in the art.

The invention also relates to a method for preparing an adenovirus according to the invention, according to which: the genome of said adenovirus is transfected into a cell line
suitable, said transfected cell line is grown under appropriate conditions.
to allow the production of said adenovirus, and - said adenovirus is recovered in the culture of said cell line
transfected and optionally substantially purified said adenovirus.

 The choice of the cell line depends on the deficient functions of the adenovirus according to the invention and use will be made of a complementation line capable of providing in trans the defective function (s). Line 293 is suitable to complement the El function (Graham et al., 1977, J. Gen. Virol 36, 59-72). For a double deficiency E1 and E2 or E4, one can use a line among those described in the French patent application 96 04413. It is also possible to use an auxiliary virus to complement the defective adenovirus according to the invention in a host cell. any or a mixed system using complementation cell and ancillary virus in which the elements are dependent on each other. The means of propagation of a defective adenovirus are known to those skilled in the art which can refer, for example, to Graham and Prevec, 1991, Methods in Molecular Biology, Vol. 7, p. 190-128; Ed E. J. Murey, The Human Press Inc.). The adenoviral genome is preferably reconstituted in vitro in Escherichia coli (E.

coli) by ligation or homologous recombination (see for example the French application 94 14470). The purification processes are described in the state of the art. One can quote the technique of centrifugation on density gradient.

The present invention also relates to a cell line comprising either in integrated form in the genome or in the form of an episome a DNA fragment coding for a fiber according to the invention placed under the control of elements allowing its expression. Said line may derive from a complementation cell of one or more adenoviral functions selected from those coded by the E1 regions,
E2, E4 and L1-L5. It is preferably derived from line 293. Such a line may be useful for the preparation of an adenovirus whose genome is devoid of all or part of the sequences coding for the fiber (so as to produce a non-functional fiber). The subject of the present invention is also the corresponding method, according to which: the genome of said adenovirus is transfected into a cell line according to
the invention, said transfected cell line is cultivated under appropriate conditions
to allow the production of said adenovirus, and - said adenovirus is recovered in the culture of said cell line
transfected and optionally substantially purified said adenovirus.

 The present invention also covers a host cell that can be infected with an adenovirus according to the invention or that can be obtained by a process according to the invention. It is advantageously a mammalian cell and, in particular, a human cell. It may be primary or tumor and of any origin, for example hematopoietic (totipotent stem cell, leukocyte, lymphocyte, monocyte or macrophage ...), muscle, nasal, pulmonary, tracheal, hepatic, epithelial or fibroblast.

 The subject of the invention is also a pharmaceutical composition comprising, as a therapeutic or prophylactic agent, a host cell or an adenovirus according to the invention or obtainable by a process according to the invention, in association with an acceptable carrier from a pharmaceutical point of view. The composition according to the invention is, in particular, intended for the preventive or curative treatment of diseases such as genetic diseases (haemophilia, cystic fibrosis, diabetes or Duchenne myopathy, Becker ...), cancers, such as those induced by oncogenes or viruses, viral diseases, such as hepatitis B or C and AIDS (acquired immunodeficiency syndrome resulting from HIV infection), and recurrent viral diseases, such as viral infections caused by the virus herpes.

 A pharmaceutical composition according to the invention can be manufactured in a conventional manner. In particular, a therapeutically effective amount of the therapeutic or prophylactic agent is associated with a carrier such as a diluent. A composition according to the invention may be administered locally, systemically or by aerosol, in particular intragastric, subcutaneous, intracardiac, intramuscular, intravenous, intraperitoneal, intratumoral, intrapulmonary, intranasal or intratracheal. The administration may take place in single or repeated doses one or more times after a certain interval interval. The appropriate route of administration and dosage vary depending on various parameters, for example, the individual or the disease to be treated or the gene (s) of interest to be transferred. In particular, the viral particles according to the invention can be formulated in the form of doses of between 10 4 and 10 14 pfu (plaque-forming units), advantageously 105 and 10 13 cfu, and preferably 106 and 1012 cfu. The formulation may also include a pharmaceutically acceptable adjuvant or excipient.

 Finally, the present invention relates to the therapeutic or prophylactic use of an adenovirus or a host cell according to the invention or of an adenovirus obtainable by a process according to the invention, for the preparation of a medicament for the treatment of the human or animal body by gene therapy. According to a first possibility, the medicament can be administered directly in vivo (for example by intravenous injection, into an accessible tumor, into the lungs by aerosol, etc.). It is also possible to adopt the ex vivo approach, which consists of taking patient cells (bone marrow stem cells, peripheral blood lymphocytes, muscle cells, etc.), transfecting them or infecting them in vitro according to the techniques of the patient. art and re-administrate them to the patient.

 The invention also extends to a method of treatment according to which a therapeutically effective amount of an adenovirus or a host cell according to the invention is administered to a patient in need of such treatment.

EXAMPLES
The following examples illustrate only one embodiment of the present invention.

The constructions described below are carried out according to the general techniques of genetic engineering and molecular cloning, detailed in Maniatis et al., (1989, Laboratory Manual, Cold Spring Harbor, Cold Spring Laboratory, Press
Harbor, NY) or as recommended by the manufacturer when using a commercial kit. The cloning steps using bacterial plasmids are preferably carried out in E. coli strain 5K (Hubacek and Glover, 1970, J. Mol.

Biol. 50, 111-127) or BJ 5183 (Hanahan, 1983, J. Mol Biol 166, 557-580). This latter strain is preferably used for the homologous recombination steps. Strain NM522 (Stratagene) is suitable for the propagation of M13 phage vectors. PCR amplification techniques are known to those skilled in the art (see, for example, PCR Protocols-A guide to methods and applications, 1990, edited by Innis, Gelfand, Sninsky and White, Academic Press Inc.). With respect to restriction site repair, the technique employed consists of filling the protruding 5 'ends with the large E. Coli DNA polymerase I fragment.

coli (Klenow). The nucleotide sequences Ad5 are those used in the Genebank database under the reference M73260.

 With respect to cell biology, the cells are transfected according to standard techniques well known to those skilled in the art. The calcium phosphate technique may be mentioned (Maniatis et al., Supra), but any other protocol may also be employed, such as the DEAE dextran technique, electroporation, methods based on osmotic shock, microinjection or methods based on the use of cationic lipids. As for the growing conditions, they are classic. In the following examples, the human line 293 (ATCC CRL1573) and the murine Swiss 3T3 (ATCC CCL92), NR6 (Wells et al., 1990, Science 247: 962-964) and NR6-hEGFR ( Schneider et al., 1986, Proc Natl.

Acad. Sci. USA 83, 333-336). It is understood that other cell lines can also be used.

EXAMPLE 1 Construction of an Adenovirus with a Host Tropism
to cells expressing the GRP receptor (for gastrin
peptide releasing in English).

A. Insertion of Sequences Encoding GRP Gfibre-GRP Ligand.

The plasmid pTG6593 derives from p II (Lathe et al., 1987, Gene 57, 193-201) by introducing the complete gene coding for the Ad5 fiber in the form of an EcoRI-SmaI fragment (nucleotides (nt) 30049 to 33093). The HindIII-SmaI fragment (nt 31994-33093) is isolated and cloned in M13TG130 (Kieny et al., 1983, Gene 26, 91-99) digested with these same enzymes, to give M13TG6526. The latter is subjected to site-directed mutagenesis using the oTG7000 oligonucleotide (SEQ ID NO: 2) (kit
Sculptor, in vitro mutagenesis, Amersham) to introduce an adapter coding for a spacer arm of 12 amino acids sequence PSASASASAPGS. The mutated vector thus obtained, M13TG6527, is subjected to a second mutagenesis enabling the sequence coding for the 10 residues of the GRP peptide to be introduced (GNHWAVGHLM, Michael et al., 1995, Gene Ther., 2, 660-668). For this purpose, oligonucleotide oTG7001 (SEQ ID NO: 3) is used. The HindIII-SmaI fragment is isolated from the mutated phage M13TG6528 and introduced by the homologous recombination technique (Chartier et al., 1996, J. Virol 70, 4805-4810) into the plasmid pTG6590 carrying the Ad5 adenoviral genome fragment. extending 27081 to 35935 and linearized with MunI (32825). The SpeI-ScaI fragment (carrying the nt 27082 to 35935 of the Ad5 genome modified by introducing the spacer arm and the GRP peptide) is isolated from the previous vector designated pTG8599 and is then exchanged for the equivalent fragment of pTG6591 previously digested with these same enzymes. As a vindictive, pTG6591 comprises the wild-type adenoviral sequences of positions 21562 to 35935. We obtain pTG4600 from which the BstEII fragment (nt 24843 to 35233) is isolated. After homologous recombination with the plasmid pTG3602 which comprises the genome Ad5 (described in more detail in the international application WO96 / 17070), the vector pTG4601 is generated.

 A cassette allowing expression of the LacZ gene is introduced in place of the adenoviral region E1 by homologous recombination between ClaI-linearized plasmid pTG4601 and a BsrGI-PstI fragment comprising the LacZ gene coding for β-galactosidase under the control of the promoter. Ad2 MLP and polyadenylation signal of SV40 virus. This fragment is isolated from the vector pTG8526 containing the 5 'end of the viral genomic DNA (nt 1 to 6241) in which the El region (nt 459 to 3328) is replaced by the LacZ expression cassette. Its construction is within the reach of the skilled person. The final vector is designated pTG4628.

 The corresponding viruses AdTG4601 and AdTG4628 are obtained by transfection of the adenoviral fragments released from plasmid sequences by PacI digestion in line 293. As an indication, AdTG4601 carries the complete Ad5 genome in which the gene of the fiber comprises at its 3 'end an arm spacer followed by the GRP peptide. The recombinant virus AdTG4628 also carries the lacZ reporter gene expression cassette under the control of the adenoviral promoter MLP.

B. Study of the tropism of the virus carrying the GRP-fiber.

The presence of the GRP peptide at the level of the adenoviral fiber makes it possible to target the cells expressing on their surface the GRP receptor. The expression of the messengers coding for the latter is studied in 293 cells and in murine cells
Swiss-3T3 (Zachary et al., 1985, Proc Natl Acad Sci USA 82, 7616-7620) by
Northern blot. A mixture of 2 DNA fragments complementary to the GRP receptor coding sequence labeled by conventional 32P isotope techniques is used as the probe. As an indication, the fragments are produced by reverse PCR from total cellular RNAs using oligonucleotides oTG10776 (SEQ ID NO: 4) and oTG10781 (SEQ ID NO: 5) (Battey et al., 1991, Proc. Natl Acad Sci USA 88, 395-399, Corjay et al., 1991, J. Biol Chem.

266, 18771 - 18779). The intensity of the mRNAs detected is much greater in the case of Swiss-3T3 cells than in 293 cells, indicating overexpression of the GRP receptor by the murine line.

Competition experiments are carried out on both types of cells. The competitor is the head of Ad5 fiber produced in E.coli whose adenoviral cell receptor binding properties have been shown (Henry et al., 1994, J. Virol 68, 5239-5246). The cells in monolayer are preincubated for 30 min in the presence of PBS or increasing concentrations of head
Recombinant Ad5 (0.1 to 100 μg / ml) in DMEM medium (Gibco BRL) supplemented with 2% fetal calf serum (FCS). Then, the AdTG4628 virus whose fiber contains the GRP peptide is added to a multiplicity of infection of 0.001 infectious unit / cell for 24h at 37 ° C. The recombinant AdLacZ virus is used as a control and under the same experimental conditions. (Stratford
Perricaudet et al., 1992, J. Clin. Invest. 90, 626-630) which carries a gene of the native fiber. The cells are then fixed and the expression of the LacZ gene evaluated (Sanes et al., 1986, EMBO J. 5, 3133-3142). The number of blue cells is representative of the effectiveness of the viral infection. Competiton inhibition results in a reduction in the number of stained cells compared to an uninfected control (PBS).

 The addition of recombinant Ad5 head at a concentration of 100 μg / ml strongly inhibits 293 cell infection by AdLacZ and AdTG4628 viruses (95 and 98% inhibition rate). This suggests that the presence of the competitor prevents the interaction of the adenoviral fiber with its natural cellular receptor. On the other hand, the two viruses behave differently on Swiss-3T3 cells. The infection of the AdTG4628 virus in the presence of 100 μg / ml of the competitor is only partially inhibited whereas, under the same experimental conditions, that of the AdLacZ virus having the native fiber is totally inhibited. These results suggest that the infection of Swiss-3T3 cells by Ad4628 is partially mediated by an independent receptor, probably the GRP receptor, that these cells over-express. In conclusion, addition of the GRP ligand to the C-terminus of the fiber promotes infection of cells expressing the GRP receptor in a manner independent of the natural fiber-receptor cellular interaction.

EXAMPLE 2 Construction of an Adenovirus Having a Host Tropism
to cells expressing the EGF receptor (Epidermal
Growth Factor in English).

This example describes a fiber carrying the EGF sequences at its Cterminal end. For this, oligonucleotides oTG11065 (SEQ ID NO: 6) and oTG11066 (SEQ ID NO: 7) are used to amplify a HindIII-XbaI fragment from plasmid M13TG6527. Oligonucleotides oTG11067 (SEQ ID NO: 8) and oTG11068 (SEQ ID NO: 9) make it possible to generate an X71oI-SmaI fragment (from the stop codon to nt 33093) from M13TG6527. EOF-complementary DNA, obtained from ATCC (# 59957), is amplified as a XhoI fragment.
XbaI using oligonucleotides oTG 11069 (SEQ ID NO: 10) and oTG11070 (SEQ
ID NO: 11). The 3 fragments digested with the appropriate enzymes are then religated to give a HindIII-SmaI fragment containing the fused EGF at the C-terminal end of the fiber. The same homologous recombination procedure as that described in Example 1 is applied to replace this fragment in its genomic context.

 However, the cloning steps can be simplified by introducing a unique BstBI site into the region targeted by conventional mutagenesis techniques. PTG4609 is obtained. Homologous recombination between PtG4609 linearized with BstBI and the preceding HinmII-SmaI fragment generates plasmid pTG4225 carrying the wild-type El region. Its equivalent carrying the LacZ expression cassette pTG4226 is obtained by homologous recombination with BstBI digested pTG4213. The AdTG4225 and AdTG4226 viruses can be produced conventionally by transfection of a suitable cell line, for example overexpressing the EOF receptor.

 To test the specificity of infection of these viruses, murine fibroblast cells NR6 and NR6-hEGFR cells expressing the human EGF receptor can be used. Competitions with recombinant AdS head or with EGF allow to evaluate the intervention of natural cellular receptors and EGF to mediate virus infection.

EXAMPLE 3: Modifications of the Fiber Head to Eliminate Binding
natural cell receptor.

 The mutation of the region of the adenoviral fiber involved in the interaction with the natural cellular receptor has been undertaken in order to eliminate the ability of the fiber to bind its natural receptor and the addition of a ligand will modify the tropism of the cells. corresponding adenoviruses.

 The sequences of the Ad5 fiber coding for the region extending from residues 443 to 462 have been subjected to various mutations. The deletion of the sheet D implements the mutagenesis oligonucleotide oTG7414 (SEQ ID NO: 12) and the deletion of the CD loop the oTGA oligonucleotide (SEQ ID NO: 13). Oligonucleotide oTGB (SEQ ID NO: 14) allows the deletion of the CD loop and the D sheet.

All these oligonucleotides contain a BamHI site for easily detecting mutants and also to insert sequences coding for a ligand, for example the EGF peptide.

 Another series of modifications consists in replacing these deleted regions with the equivalent sequences derived from the Ad3 fiber. Indeed, many data show that Ad5 and Ad3 do not bind to the same receptor, so that such a substitution should abolish Ad5 receptor-mediated infection and target cells carrying the Ad3 receptor. The replacement of the AdS CD loop by that of the Ad3 implements oTG11135 (SEQ ID NO: 15), the replacement of the sheet D of the Ad5 fiber by that of the Ad3 fiber is carried out by the oligonucleotide oTG10350 (SEQ ID NO: 16) and the replacement of the D leaflet and CD loop of the Ad5 with those of the Ad3 is performed on the previous mutant using oTG11136 (SEQ ID NO: 17).

This target region of the adenoviral head has also been modified by a series of point mutations.
replacement of the AA GSLA elbow in a AA DKLT elbow: oTGC (SEQ ID NO:
18)
- replacing the elbow aa SGTV in elbow cra DKLT: oTGD (SEQ ID
NO: 19),
- G443 in D: oTGE (SEQ ID NO: 20),
L445 at F: oTGF (SEQ ID NO: 21),
G450 in N: oTGG (SEQ ID NO: 22),
T451 in K: oTGH (SEQ ID NO: 23),
V452 in N: oTGI (SEQ ID NO: 24),
A 455 in F: oGJ (SEQ ID NO: 25),
M57 to A: oTGK (SEQ ID NO: 26),
- I459 in: oTG L (SEQ ID NO: 27).

 The I-OGEs introduce mutations in the CD loop of the adenoviral fiber on amino acids that are non-conservative between Ad5 and Ad3 whereas the OTGJs to K involve amino acids of the D-sheet not engaged in a hydrogen bond. stabilizing the structure.

Mutagenesis can be carried out on the vector M13TG6526 or
M13TG6528. The first carries the wild-type HindIII-SmaI fragment and the second this same fragment modified by the insertion of the GRP sequences. The plasmids carrying the adenoviral genome can be reconstituted as previously described for the plasmids pTG4225 (wild-type E1) and pTG4226 (LacZ instead of the E1 region).

The viruses are generated by transfection of 293 cells or cells overexpressing the receptor binding the ligand of interest. Such cells can be generated by transfection of the corresponding complementary DNA. Cells which do not naturally express the natural adenovirus cell receptor, for example the Daudi line (ATCC CCL213), are preferably used.

EXAMPLE 4 Insertion of the ligand into a capsid protein other than
fiber in combination with one of the fiber modifications
above.

 This example describes the insertion of the EGF ligand into the hexon capsid protein. Of course, it is preferable that the corresponding adenovirus has lost its ability to attach to the natural cellular receptor. Its genome may for example include a gene of the modified fiber (see Example 3) or be devoid of at least part of the sequences of the fiber.

A transfer plasmid for homologous recombination covering the region of the AdS genome encoding hexon (nt 18842-21700) is constructed. The HindIII-XhoI AdS fragment (nt 18836-24816) is cloned into pBSK + (Stratagene) digested with these same enzymes to give the plasmid pTG4224. The sequences coding for the EGF peptide are introduced into the hypervariable loop L1 of the hexon by creation of chimeric fragments by PCR: hexon (nt19043-19647)
XbaI-EGF-BsrGI-hexon (nt19699-20312). The nt19043 to 19647 fragment is obtained by PCR amplification from the plasmid pTG3602 with oligonucleotides oTG11102 (SEQ ID NO: 28) and oTG11103 (SEQ ID NO: 29). The nt19699 to 20312 fragment is amplified from the same DNA with oligonucleotides oTG11104 (SEQ ID NO: 30) and oTG11105 (SEQ ID NO: 31). EGF is cloned from cDNA using oligonucleotides oTG11106 (SEQ ID NO: 32) and oTG11107 (SEQ ID NO: 33) to bring the EGF coding sequence in phase with hexon. The PCR products are digested with the appropriate enzymes and then religated. The chimeric fragment may then be inserted by homologous recombination into the NdeI linearized plasmid pTG4224 (No. 19549), to give pTG4229. The sequences encoding the modified hexon can be obtained by HindIII-XhoI digestion and replaced in their genomic context by homologous recombination. The S-linearized vector pTG3602, pTG4607, pTG4629 or a vector carrying the adenoviral genome deleted from the fiber sequences (such as pTG4607 described below) or expressing a modified fiber according to Example 3 can be used.

The adenoviral genome incapable of producing a functional native fiber is obtained by a deletion affecting the initiator codon but not extending to other adenoviral ORFs. The procedure is as follows: the adenoviral fragment 5 'of the deletion (nt 30564 to 31041) is amplified by PCR using primers oTG7171 and oTG7275 (SEQ ID NO: 34 and 35). Amplification of the 3 'fragment (nt 31129 to 33099) implements primers oTG7276 and oTG7049 (SEQ ID NO: 36 and 37). The PCR fragments are digested with XhoI and ligated before being introduced by homologous recombination into the linearized vector pTG6591.
NdeI, to give pTG4602. Then, the BstEII fragment isolated from the latter is subjected to homologous recombination with the SpeI digested pTG3602 vector. PTG4607 is obtained. The vector pTG4629 is equivalent to pTG4607, but also carries the LacZ expression cassette in place of El.

 The corresponding viruses can be obtained after transfection of 293 cells or cells overexpressing the EGF receptor. The study of the specificity of infection can be carried out as previously described using EGF as a competitor.

SEQUENCE LIST (1) GENERAL INFORMATION:
(i) DEPOSITOR:
(A) NAME: Transgene SA
(B) STREET: 11 rue de Molsheim
(C) CITY: Strasbourg
(E) COUNTRY: France
(F) POSTAL CODE: 67000
(G) TELEPHONE: (33) 03 88 27 91 00
(H) FAX: (33) 03 88 27 91 11
(A) NAME: National Center for Scientific Research
(CNRS)
(B) STREET: 3 Michael Angel Street
(C) CITY: Paris
(E) COUNTRY: France
(F) POSTAL CODE: 75794 Cedex 16
(G) TELEPHONE: (33) 01 44 96 40 00
(H) FAX: (33) 01 44 96 50 00
(ii) TITLE OF THE INVENTION: Adenoviral modified fiber and adenovirus
targets
(iii) NUMBER OF SEQUENCES: 37
(iv) COMPUTER-READABLE FORM:
(A) SUPPORT TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS / MS-DOS
(D) SOFTWARE: PatentIn Release # 1.0, Version # 1.25 (EPO) (2) INFORMATION FOR SEQ ID NO: 1:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 581 amino acids
(B) TYPE: amino acid
(D) CONFIGURATION: linear
(ii) TYPE OF MOLECULE: protein
(iii) Hypothesis: No
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: adenovirus 5
(C) INDIVIDUAL ISOLATED: fiber Ad5 (xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 1:
Met Arg Lys Arg Ala Pro Arg Glu Asp Thr Phe Asn Pro Val Tyr Pro
1 5 10 15
Tyr Asp Thr Glu Thr Pro Gly Pro Thr Pro Pro Pro Phe Leu Thr Pro Pro
20 25 30
Phe Val Ser Asn Pro Gly Phe Gln Pro Ser Ser Pro Gly Val Leu Ser
35 40 45
Leu Arg Leu Ser Glu Pro Leu Val Thr Ser Asn Gly Met Leu Ala Leu
50 55 60
Lys Met Gly Asn Gly Leu Ser Asp Asp Glu Ala Gly Asn Leu Thr Ser
65 70 75 80
Gln Asn Thr Thr Val Val Pro Pro Pro Lys Lys Thr Lys Ser Asn
85 90 95
Ile Asn Leu Glu Ser Ser Ala Pro Leu Thr Leu Thr Thr Glu Ala Leu
100 105 110
Thr Val Ala Ala Ala Ala Pro Leu Val Ala Gly Asn Thr Leu Thr
115 120 125
Gln Ser Gln Ala Pro Leu Thr Val His Asp Ser Lys Leu Ser Ile
130 135 140
Ala Thr Gln Gly Pro Leu Thr Val Ser Glu Gly Lys Leu Ala Leu Gln
145 150 155 160
Thr Ser Gly Pro Leu Thr Asp Thr Thr Ser Ser Thr Thr Leu Thr Thr Thr
165 170 175
Ala Ser Pro Leu Leu Thr Thr Ala Thr Gly Leu Leu Gly Ile Asp Leu
180 185 190
Lys Glu Pro Tyr Thr Gln Asn Gly Lys Leu Gly Leu Lys Tyr Gly
195 200 205
Ala Pro Leu His Asp Asp Asp Leu Leu Thr Thr Val Ala Thr
210 215 220
Gly Pro Gly Val Thr Asn Asn Thr Thr Leu Gln Thr Lys Val Thr
225 230 235 240
Gly Ala Leu Gly Phe Asp Ser Gln Gly Asn Met Gln Leu Asn Val Ala
245 250 255
Gly Gly Leu Arg Asp Asp
Ser Tyr Pro Phe Asp Ala Gln Asn Gln Leu Asn Leu Arg Leu Gly Gln
275 280 285
Gly Pro Leu Phe Asn Ser Ala His Asn Leu Asp Asn Asn Tyr Asn
290,295,300
Lys Gly Leu Tyr Phe Thr Ala Ser Asn Asn Ser Lys Leu Leuk 305 310 315 320
Val Asn Leu Ser Thr Ala Lys Gly Leu Met Phe Asp Ala Thr Ala Ile
325 330 335
Ala Asn Ala Gly Asp Gly Leu Glu Phe Gly Pro Asn Ala Pro
340,345,350
Asn Thrn Asn Pro Leu Lys Thr Lys Island Gly His Gly Leu Glu Phe Asp
355 360 365
Ser Asn Lys Ala Met Pro Val Lys Leu Gly Thr Serly Gly Leu Phe Asp
370,375,380
Ser Thr Gly Ala Thr Thread Gly Asn Lys Asn Asn Asp Lys Leu Thr 385 390 395 400
Leu Trp Thr Thr Pro Ala Pro Pro Asn Cys Arg Leu Asn Ala Glu
405 410 415
Lys Asp Ala Lys Leu Leu Leu Leu Leu Lys Lys Cys Gly Ser Gln Ile
420,425,430
Leu Ala Thr Ser Val Val Leu Ala Val Lys Gly Leu Leu Ala Pro Ile
435 440 445
Ser Gly Thr Val Gln Ser Ala His Leu Island Isle Arg Phe Asp Glu Asn
450 455 460
Gly Leu Leu Val Asn Asn Phe Leu Asp Asp Glu Tyr Trp Asn Phe 465 470 475 480
Arg Asn Gly Asp Leu Thr Glu Gly Thr Ala Tire Thr Asn Ala Val Gly
485 490 495
Phe Met Pro Asn Leu Ser Ala Tyr Pro Lys Ser His Gly Lys Thr Ala
500 505 510
Lys Ser Asn Island Val Ser Gln Val Tyr Asn Leu Gly Asp Lys Thr Lys
515 520 525
Pro Thr Thr Leu Thr Thr Leu Asn Gly Gln Gl Thr Thr Asp
530,535,540
Thr Thr Pro Ser Ala Ser Ser Ser Ser Phe Ser Trp Asp Trp Ser Gly 545 550 555 560
His Asn Tire Island Asn Glu Island Phe Ala Thr Ser Ser Tyr Thr Phe Ser
565 570 575
Tire Island Ala Gln Glu
580
(2) INFORMATION FOR SEQ ID NO: 2:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 60 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTG7000
(code for PSASASASAPGS)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 2:
AACGATTCTT TAGCTGCCGG GAGCAGAGGC GGAGGCGGAG GCGCTGGGTT CTTGGGCAAT 60
(2) INFORMATION FOR SEQ ID NO: 3:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 57 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide otg7001
(code for GRP)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 3:
AACGATTCTT TACATCAGGT GGCCCACAGC CCAGTGGTTT CCGCTGCCGG GAGCAGA 57 (2) INFORMATION FOR SEQ ID NO: 4:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENSES: NO
(vi) ORIGIN:
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTG10776
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 4:
CCTTCCACGG GAAGATTGTA (2) INFORMATION FOR SEQ ID NO: 5:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTG10781
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 5: GGGGTGTCTG TCTTCACACT (2) INFORMATION FOR SEQ ID NO: 6:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 26 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENSES: NO
(vi) ORIGIN:
(C) ISOLATED INDIVIDUAL: synthetic oligonucleotide oTG11065
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 6: GGGAAGCTTG AGGTTAACCT AAGCAC 26 (2) INFORMATION FOR SEQ ID NO: 7:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(C) ISOLATED INDIVIDUAL: synthetic oligonucleotide oTG11066
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 7: GGGTCTAGAG CTGCCGGGAG CAGAGGCG 28 (2) INFORMATION FOR SEQ ID NO: 8:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENSES: NO
(vi) ORIGIN:
(C) ISOLATED INDIVIDUAL: synthetic oligonucleotide oTG11067
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 8:
GGGCTCGAGT TATGTTTCAA CGTGTTTAT 29 (2) INFORMATION FOR SEQ ID NO: 9:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTG11068
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 9:
GTGCCCGGGG AGTTTATTAA TATC 24 (2) INFORMATION FOR SEQ ID NO: 10:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 31 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) TYPE OF MOLECULE: cDNA
(iii) Hypothesis: No
(iii) ANTI-SENSES: NO
(vi) ORIGIN:
(A) ORGANIZATION: Homo sapiens
(C) ISOLATED INDIVIDUAL: synthetic oligonucleotide oTG11069
(EGF cloning)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 10:
GCGTCTAGAA ATAGTGACTC TGAATGTCCC C 31 (2) INFORMATION FOR SEQ ID NO: 11:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 46 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) TYPE OF MOLECULE: cDNA
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANIZATION: Homo sapiens
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTG11070
(EGF cloning)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 11:
CTGAGC ACAAACGATT CTTTAGCGCA GTTCCCACCA CTTCAG 46 (2) INFORMATION FOR SEQ ID NO: 12:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: adenovirus 5
(C) ISOLATED INDIVIDUAL: synthetic oligonucleotide oTG7414
(deletion of slip D)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 12:
TAGCACTCCA TTTTCGTCGG ATCCTTGAAC TGTTCCAGAT AT 42 (2) INFORMATION FOR SEQ ID NO: 13:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 43 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: adenovirus 5 (Ad5)
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTGA
(deletion of the CD loop)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 13:
CTTATAATAA GATGAGCACT GGATCCAGCC AAAACTGAAA CTG 43 (2) INFORMATION FOR SEQ ID NO: 14:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 45 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: adenovirus 5 (Ad5)
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTGB
(deletion loop CD and fD)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 14:
GTAGCACTCC ATTTTCGTCG GATCCAACAG CCAAAACTGA AACTG 45 (2) INFORMATION FOR SEQ ID NO: 15:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 88 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: Ad3 Human Adenovirus
(C) ISOLATED INDIVIDUAL: synthetic oligonucleotide oTG11135
(CD5 loop in CD3)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 15:
CGTCAAATCT TATAATAAGA TGAGCACTCA CGTTTTTGTT TTTAAACAGG GTGTTGTAGT 60 CGCTAACAGC CAAAACTGAA ACTGTAGC 88
(2) INFORMATION FOR SEQ ID NO: 16:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 64 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANISM: Adenovirus (Mastadenovirus)
(B) STRAIN: Adenovirus 3
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTG10350
(sheet D5 in D3)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 16:
GTAGCACTCC ATTTTCGTCA AAGTAGAGCT CCACGTTGAT ACTTTGAACT GTTCCAGATA 60
TTGG 64
(2) INFORMATION FOR SEQ ID NO: 17:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 88 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: Adenovirus Ad3
(C) ISOLATED INDIVIDUAL: synthetic oligonucleotide oTG11136
(CD + D5 on CD + D3)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 17:
CGTCAAAGTA GAGCTCCACG TTGATACTCA CGTTTTTGTT TTTAAACAGG GTGTTGTAGT 60
CGCTAACAGC CAAAACTGAA ACTGTAGC 88 (2) INFORMATION FOR SEQ ID NO: 18:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 56 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: Adenovirus 5
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTGC
(replace GSLA elbow in DKLT)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 18:
TTGAACTGTT CCAGATATTG GGGTCAGTTT GTCTTTAACA GCCAAAACTG AAACTG 56 (2) INFORMATION FOR SEQ ID NO: 19:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 48 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: Adenovirus 5 (Ad5)
(C) ISOLATED INDIVIDUAL: synthetic oligonucleotide oTGD
(replace SGTV elbow in DKLT)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 19:
AATAAGATGA GCACTTTGGG TCAGTTTGTC TATTGGAGCC AAACTGCC 48 (2) INFORMATION FOR SEQ ID NO: 20:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 44 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: Adenovirus 5
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTGE
(replace G443 in D)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 20:
CCAGATATTG GAGCCAAACT GTCTTTAACA GCCAAAACTG AAAC 44 (2) INFORMATION FOR SEQ ID NO: 21:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: Adenovirus 5 (Ad5)
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTGF
(replaces L445 in F)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 21:
TGTTCCAGAT ATTGGAGCGA AACTGCCTTT AACAGCCAAA AC 42
(2) INFORMATION FOR SEQ ID NO: 22:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: Adenovirus 5 (Ad5)
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTGG
(replace G450 in N)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 22:
ATGAGCACTT TGAACTGTGT TAGATATTGG AGCCAAACTG CC 42
(2) INFORMATION FOR SEQ ID NO: 23:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 44 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: Adenovirus 5 (Ad5)
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTGH
(replace T451 in K)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 23:
TAGATGAGC ACTTTGAACC TTTCCAGATA TTGGAGCCAA ACTG 44 (2) INFORMATION FOR SEQ ID NO: 24:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 45 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: Adenovirus 5 (Ad5)
(C) ISOLATED INDIVIDUAL: synthetic oligonucleotide oTGI
(replace V452 in N)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 24:
CTTATAATAA GATGAGCACT TTGGTTTGTT CCAGATATTG GAGCC 45 (2) INFORMATION FOR SEQ ID NO: 25:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 48 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: Adenovirus 5
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTGJ
(replace A455 in F)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 25:
GFCAAATCTT ATAATAAGAT GGAAACTTTG AACTGTTCCA GATATTGG 48 (2) INFORMATION FOR SEQ ID NO: 26:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 47 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: Adenovirus 5
(C) ISOLATED INDIVIDUAL: oTGK synthesis oligonucleotide
(replace L457 in A)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 26:
CCATTTTCGT CAAATCTTAT AATTTTATGA GCACTTTGAA CTGTTCC 47 (2) INFORMATION FOR SEQ ID NO: 27:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 46 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: Adenovirus 5 (Ad5)
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTGL
(replace I459 in A)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 27: GCACTCCATT TTCGTCAAAT CTAGCAATAA GATGAGCACT TTGAAC 46 (2) INFORMATION FOR SEQ ID NO: 28:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENSES: NO
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: Adenovirus 5 (Ad5)
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTG11102
(hexon cloning)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 28:
CGGTTCATCC CTGTGGACCG TGA 23 (2) INFORMATION FOR SEQ ID NO: 29:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: Adenovirus 5 (Ad5)
(C) ISOLATED INDIVIDUAL: synthetic oligonucleotide oTG11103
(hexon cloning)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 29:
GGCCTCTAGA GTTGAGAAAA ATTGCATTTC CACTTGAC 38 (2) INFORMATION FOR SEQ ID NO: 30:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENSES: NO
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: Adenovirus 5 (Ad5)
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTGl1104
(hexon cloning)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 30:
GGTATTGTAC AGTGAAGATG TAG 23 (2) INFORMATION FOR SEQ ID NO: 31:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 23 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: Adenovirus 5 (Ad5)
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTG11105
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 31:
CGTTGGAAGG ACTGTACTTT AGC 23 (2) INFORMATION FOR SEQ ID NO: 32:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) TYPE OF MOLECULE: cDNA
(iii) Hypothesis: No
(iii) ANTI-SENSES: NO
(vi) ORIGIN:
(A) ORGANIZATION: Homo sapiens
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTG11106
(EGF cDNA cloning)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 32:
CGCGTCTAGA GGCGAATAGT GACTCTGAAT GTCCCCTG 38 (2) INFORMATION FOR SEQ ID NO: 33:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 45 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) TYPE OF MOLECULE: cDNA
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANIZATION: Homo sapiens
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTG11107
(EGF cDNA cloning)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 33:
CCACTGTACA ATACCACTTT AGGGCGCAGT TCCCACCACT TCAGG 45 (2) INFORMATION FOR SEQ ID NO: 34:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 21 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENSES: NO
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: Adenovirus 5 (Ad5)
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTG7171
(deletion of the fiber)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 34:
ATGGTTAACT TGCACCAGTG C 21
(2) INFORMATION FOR SEQ ID NO: 35:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: Adenovirus 5 (Ad5)
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTG7275
(deletion of the fiber)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 35: GGGCTCGAGC TGCAACAACA TGAAGAT 27
(2) INFORMATION FOR SEQ ID NO: 36:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENSES: NO
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: Adenovirus 5 (Ad5)
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTG7276
(deletion of the fiber)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 36:
CCGCTCGAGA CTCCTCCCTT TGTATCC 27 (2) INFORMATION FOR SEQ ID NO: 37:
(i) CHARACTERISTICS OF THE SEQUENCE:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) NUMBER OF BRINS: simple
(D) CONFIGURATION: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) Hypothesis: No
(iii) ANTI-SENS: YES
(vi) ORIGIN:
(A) ORGANISM: Mastadenovirus
(B) STRAIN: Adenovirus 5 (Ad5)
(C) INDIVIDUAL ISOLATED: synthetic oligonucleotide oTG7049
(deletion of the fiber)
(xi) DESCRIPTION OF THE SEQUENCE: SEQ ID NO: 37:
CTGCCCGGGA GTTTATTAAT 20

Claims (32)

claims  1. Fiber of an adenovirus modified by mutation of one or more residues of said  fiber, characterized in that said mutated residues are directed to the receiver  natural cell of said adenovirus. 2. Fiber of an adenovirus according to claim 1, characterized in that it is  modified by mutation of one or more residues between the CD loop and  the sheet ss I of said fiber and, preferably between the CD and DG loops. 3. Fiber of an adenovirus according to claim 2, characterized in that it drifts  of an adenovirus type 5 fiber (Ad5) comprising all or part of the  sequence as shown at Sequence ID No. 1 (SEQ ID NO: 1)  and that it is modified by mutation of one or more residues of the region  between residues 441 and 557. 4. Fiber of an AdS adenovirus according to claim 3, characterized in that  is modified by mutation of one or more residues from the region between  residues 441 to 478 of SEQ ID NO: 1 and preferably 443 to 462. 5. Fiber of an AdS adenovirus according to claim 4, characterized in that  is changed by substitution  the glycine residue at position 443 with an aspartic acid residue,  the leucine residue at position 445 with a phenylalanine residue,  the glycine residue at position 450 with an asparagine residue,  the threonine residue at position 451 with a lysine residue,  the valine residue at position 452 with an asparagine residue,  the alanine residue at position 455 with a phenylalanine residue,  the leucine residue at position 457 with an alanine residue, and / or  the isoleucine residue at position 459 with an alanine residue. 6. Fiber of an adenovirus Ad5 according to claim 4, characterized in that  is changed by substitution  the glycine residue at position 443 with an aspartic acid residue,  the serine residue at position 444 with a lysine residue, and  the alanine residue at position 446 with a threonine residue  or  the serine residue at position 449 with an aspartic acid residue,  the glycine residue at position 450 with a lysine residue,  threonine residue at position 451 with a leucine residue, and  the valine residue at position 452 with a threonine residue. 7. Fiber of an AdS adenovirus according to claim 4, characterized in that  is modified by deletion  - from the region extending from the serine at position 454 to phenylalanine  in position 461,  from the region extending from valine at position 441 to glutamine in  position 453, or  - from the region extending from valine at position 441 to phenylalanine  in position 461. 8. Fiber of an adenovirus according to claim 2, characterized in that it drifts  of a type 2 adenovirus (Ad2) fiber and that it is modified by mutation  one or more residues from the region between residues 441 and 558 of  said fiber. 9. Fiber of an Ad2 adenovirus according to claim 8, characterized in that  is modified by mutation of one or more residues from the region between  residues 441 to 478 and, preferably, 451 to 466 of said fiber. 10. Fiber of an adenovirus according to one of claims 1 to 9, characterized in that  that at least one of the modifications is a deletion of at least 3 residues  consecutive of a loop and / or a sheet of said fiber and that said residues  deleted are replaced by residues of a loop and / or leaflet  equivalent derived from a fiber of a second adenovirus, in particular of type 3 or 7,  likely to interact with a cellular receiver different from the first  adenoviruses. 11. Fiber of an adenovirus characterized in that it has a binding capacity to  natural cell receptor substantially reduced and that it is capable of  trimerized. 12. Fiber of an adenovirus according to one of claims 1 to 11, characterized in that  it further comprises a ligand capable of recognizing a molecule of  cell surface different from the natural cellular receptor of said adenovirus. 13. Fiber of an adenovirus according to claim 12, characterized in that the ligand  is selected from the group consisting of an antibody, a peptide, a  hormone, a polypeptide or a sugar. 14. Fiber of an adenovirus according to claim 12 or 13, characterized in that the  ligand is inserted at the C-terminus of the fiber or, where at least one  modifications is a deletion of at least 3 consecutive residues, in  replacement of the deleted residues. 15. DNA Fragment or Expression Vector Coding for a Fiber of an Adenovirus  according to one of claims 1 to 14.  cellular.  placed under the control of the elements allowing its expression in said line  the genome or as an episome a DNA fragment according to claim 15  16.Cell cell line characterized in that it comprises either in an integrated form in 17. The cell line according to claim 16, characterized in that it is in  additionally capable of complementing a deficient adenovirus for one or more  functions selected from the functions encoded by the regions E1, E2, E4 and L1-L5. 18. The cell line according to claim 16 or 17, characterized in that it drifts  from line 293. 19. Adenovirus characterized in that it lacks a functional native fiber and  it comprises a fiber according to one of claims 1 to 14, said fiber according to  one of claims 1 to 14 being codable by the genome of said adenovirus  or provided in trans by a cell line according to one of claims 16 to  18. 20. Adenovirus characterized in that it lacks a functional fiber and  it comprises a fiber according to one of claims 1 to 14 and a ligand  capable of recognizing a cell surface molecule different from the receptor  natural cell of said adenovirus. 21. Adenovirus according to claim 20, characterized in that the ligand is  selected from the group consisting of an antibody, a peptide, a hormone,  a polypeptide or a sugar. 22. Adenovirus according to one of claims 20 and 21, characterized in that the  ligand is inserted at the C-terminus of the fiber or, where at least one  modifications is a deletion of at least 3 consecutive residues, in  replacement of the deleted residues. 23. Adenovirus according to one of claims 19 to 21, characterized in that the  ligand is inserted into a capsid protein other than fiber, in particular  the hexon or the penton. 24. Adenovirus according to one of claims 19 to 23, characterized in that it is  a recombinant adenovirus defective for replication. 25. Adenovirus according to claim 24, characterized in that it is deleted from all  or part of the region E1 and, optionally, all or part of the region E3. 26. Adenovirus according to claim 25, characterized in that it is furthermore deleted  all or part of the region E2, E4 and / or L1-L5. 27. Adenovirus according to one of claims 24 to 26, characterized in that  comprises a gene of interest selected from the genes encoding a  cytokine, a cellular or nuclear receptor, a ligand, a  coagulation, CFTR protein, insulin, dystrophin, a hormone  growth, an enzyme, an enzyme inhibitor, an antidepressant polypeptide  tumor, a polypeptide capable of inhibiting a bacterial, parasitic infection  or viral and, in particular HIV, an antibody, a toxin, an immunotoxin and  a marker. 28. Process for producing an adenovirus according to one of claims 19 to 27,  characterized in that  the genome of said adenovirus is transfected into a cell line  appropriate,  said transfected cell line is cultured under conditions  suitable for the production of said adenovirus, and  said adenovirus is recovered from said culture of said line  transfected cell and, optionally, substantially purifies  said adenovirus. 29. Process for producing an adenovirus whose genome is devoid of all or  part of the coding sequences for a fiber, characterized in that  the genome of said adenovirus is transfected into a cell line  according to one of claims 16 to 18,  said transfected cell line is cultured under conditions  suitable for the production of said adenovirus, and  said adenovirus is recovered in the culture of said cell line  transfected and, if appropriate, substantially purified  adenoviruses. 30. Adenovirus-infectable host cell according to one of claims 19 to 27  or obtainable by a process according to claim 28 or 29. 31. A pharmaceutical composition comprising an adenovirus according to one of the  claims 19 to 27 or obtainable by a method according to  claim 28 or 29 or a host cell according to claim 30 in  combination with a pharmaceutically acceptable carrier. 32. Therapeutic or prophylactic use of an adenovirus according to one of the  claims 19 to 27 or obtainable by a method according to  claim 28 or 29 or a host cell according to claim 30, for the  preparation of a medicament for the treatment of the human or animal body by  genetical therapy.